• Home
  • About
  • Resources for States
    • Issue Briefs
    • Templates & Toolkits
    • Webinars
  • Expert Perspectives
  • Contact
  • COVID-19
  • Health Equity

Federal Statute and Guidance | Covid-19 | Apr 27, 2020

FAQs: Provision of Methadone and Buprenorphine for the Treatment of Opioid Use Disorder in the COVID-19 Emergency

Substance Abuse and Mental health Services Administration (SAMHSA)

This FAQ answers common provider questions regarding the provision of methadone and buprenorphin, including through the use of telehealth, for the treatment of opioid disorder during the COVID-19 crisis.

Privacy Policy
Terms of Use

© 2019 State Health and Value Strategies is a program of the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Stay in Touch

Subscribe to periodic email updates.